Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904136 | 0.83 | HTR6 (0.38) | HTR6HTR2ASIGMAR1 | |
| SCHEMBL617432 | 0.77 | HTR6 (0.30) | HTR6HTR2A | |
| SCHEMBL1921591 | 0.74 | HTR2A (0.38) | HTR6HTR2ASIGMAR1 | |
| SCHEMBL8677603 | 0.73 | HTR6 (0.33) | HTR6HTR2ASIGMAR1 | |
| SCHEMBL9860034 | 0.73 | HTR2A (0.37) | HTR6HTR2ASIGMAR1 | |
| SCHEMBL8380397 | 0.72 | HTR6 (0.32) | HTR6HTR2ASIGMAR1 | |
| SCHEMBL6673086 | 0.71 | HTR2A (0.36) | HTR6HTR2ASIGMAR1 | |
| SCHEMBL8384531 | 0.71 | HTR2A (0.36) | HTR6HTR2ASIGMAR1 | |
| SCHEMBL820680 | 0.71 | HTR2A (0.33) | HTR6HTR2A | |
| SCHEMBL3383301 | 0.71 | HTR2A (0.38) | HTR6HTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3480258-B1 | SOLID MAO COMPOSITION CONTAINING AL2O3 AND METHOD FOR PRODUCING SAME | TOSOH FINECHEM CORP (JP) | 2023-12-20 | — | — | EP | disclosed |
| US-20230137384-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20210283172-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. | 2021-09-16 | — | — | US | disclosed |
| US-10730969-B2 | Solid MAO composition containing Al2O3 and method for producing same | TOSOH FINECHEM CORPORATION (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-3318544-B1 | PROCESS FOR THE PREPARATION OF POLYMERIZED POLYETHYLENE WAX | SCG CHEMICALS CO LTD (TH) | 2020-03-18 | — | — | EP | disclosed |
| EP-3609483-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | Urigen Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190263947-A1 | PROCESS FOR THE PREPARATION OF POLYMERIZED POLYETHYLENE WAX | SCG CHEMICALS CO., LTD. (TH) | 2019-08-29 | — | — | US | disclosed |
| WO-2018191412-A9 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| EP-3480258-A1 | SOLID MAO COMPOSITION CONTAINING AL2O3 AND METHOD FOR PRODUCING SAME | Tosoh Finechem Corporation (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-20180355077-A1 | SOLID MAO COMPOSITION CONTAINING AL2O3 AND METHOD FOR PRODUCING SAME | TOSOH FINECHEM CORPORATION (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-0327649-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND PROCESS FOR ITS PREPARATION | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-08-16 | — | — | EP | disclosed |
| EP-0328348-A2 | Olefin polymerization catalyst and process for the polymerization of olefins | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-08-16 | — | — | EP | disclosed |
| EP-0324856-A1 | PROCESS FOR POLYMERIZING OLEFIN | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-07-26 | — | — | EP | disclosed |
| EP-0314797-A1 | OLEFIN POLYMERIZATION CATALYST AND PROCESS FOR POLYMERIZING OLEFIN | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-05-10 | — | — | EP | disclosed |
| EP-0295312-A1 | SOLID CATALYST FOR OLEFIN POLYMERIZATION AND PROCESS FOR ITS PREPARATION | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-12-21 | — | — | EP | disclosed |
| EP-0294942-A1 | Solid catalyst for polymerizing an olefin | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-12-14 | — | — | EP | disclosed |
| EP-0287666-A1 | PROCESS FOR POLYMERIZING OLEFINS | Mitsui Chemicals, Inc. (JP) | 1988-10-26 | — | — | EP | disclosed |
| EP-0283164-A2 | Cyclo-olefinic random copolymer, olefinic random copolymer, and process for producing cyclo-olefinic random copolymers | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-09-21 | — | — | EP | disclosed |
| EP-0279863-A1 | CATALYST FOR POLYMERIZING ALPHA-OLEFIN AND POLYMERIZATION PROCESS | MITSUI CHEMICALS, INC. (JP) | 1988-08-31 | — | — | EP | disclosed |
| EP-0279586-A2 | Finely divided aluminoxane, process for producing same and its use | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283172-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | OGFR, ALOX5, PTGS1 | HTR6 2080/4885HTR2A 2553/4885SIGMAR1 151/4885 |
| US-20230137384-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | OGFR, ALOX5, PTGS1 | HTR6 2080/4885HTR2A 2553/4885SIGMAR1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.